Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants

Journal of Clinical Pharmacology

Volumn 49, Issue 12, 2009, Pages 1447-1455

  Vakily, Majid ^a   Wu, Jingtao ^a   Atkinson, Stuart N ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Dexlansoprazole; Dexlansoprazole MR; Proton pump inhibitor; QT interval; TAK 390

Indexed keywords

DEXLANSOPRAZOLE MR; MOXIFLOXACIN; PLACEBO; PROTON PUMP INHIBITOR; TAK 390 MR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 70349394067     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009339188     Document Type: Article

References (27)

1. Woosley RL, Chen Y., Freiman JP, Gillis RA Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993 ; 269: 1532-1536. 2.
2. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M., Fulton DR, Berul CI Proarrhythmia associated with cisapride in children. Pediatrics. 1998 ; 101: 1053-1056.
3. Piquette RK Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother. 1999 ; 33: 22-26.
4. Vitola J., Vukanovic J., Roden DM Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol. 1998 ; 9: 1109-1113.
5. Wysowski DK, Corken A., Gallo-Torres H., Talarico L., Rodriguez EM Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol. 2001 ; 96: 1698-1703.
6. Falagas ME, Rafailidis PI, Rosmarakis ES Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007 ; 29: 374-379.
7. Wiley JF II, Gelber ML, Henretig FM, Wiley CC, Sandhu S., Loiselle J. Cardiotoxic effects of astemizole overdose in children. J Pediatr. 1992 ; 120: 799-802.
8. Guelon D., Bedock B., Chartier C., Haberer JP QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion. Am J Cardiol. 1986 ; 58: 666.
9. Huang BH, Hsia CP, Chen CY Sulpiride induced torsade de pointes. Int J Cardiol. 2007 ; 118: e100 - e102.
10. US Food and Drug Administration (FDA). Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville, MD: FDA ; 2005.
11. Zhang W., Wu J., Atkinson S. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology. 2007 ; 132: A487.
12. Avelox« (moxifloxacin) [full prescribing information]. West Haven, CT: Bayer Pharmaceuticals Corp ; 2005.
13. Zambruni A., Di Micoli A., Lubisco A., Domenicali M., Trevisani F., Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007 ; 18: 77-82.
14. Wolbrette DL Drugs that cause torsades de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep. 2004 ; 6: 379-384.
15. Moss AJ The QT interval and torsade de pointes. Drug Saf. 1999 ; 21: 5-10.
16. Naesens M., Kuypers DR, Streit F., et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther. 2006 ; 80: 509-521.
17. Enger C., Cali C., Walker AM Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf. 2002 ; 11: 477-486.
18. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem ? J Electrocardiol. 2004 ; 37: 15-24.
19. Hondeghem LM Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol. 2006 ; 17: 337-340.
20. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol. 1999 ; 10: 272-282.
21. Tamargo J., Caballero R., Gomez R., Valenzuela C., Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004 ; 62: 9-33.
22. Thomas D., Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des. 2006 ; 12: 2271-2283.
23. Hancox JC, Mitcheson JS Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br J Pharmacol. 2006 ; 149: 457-459.
24. Perry M., Stansfeld PJ, Leaney J., et al. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol. 2006 ; 69: 509-519.
25. Ferron GM, Paul JC, Fruncillo RJ, Martin PT, Yacoub L., Mayer PR Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J Clin Pharmacol. 1999 ; 39: 945-950.
26. Hasselgren B., Claar-Nilsson C., Hasselgren G., Niazi M., Svernhage E. Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin Drug Investig. 2000 ; 20: 425-431.
27. Katsuki H., Yagi H., Arimori K., et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996 ; 13: 611-615.